| Literature DB >> 33715099 |
Ricardo Salgado-Aranda1, Nicasio Pérez-Castellano2,3,4,5, Ivan Núñez-Gil2, A Josué Orozco2, Norberto Torres-Esquivel2, Jesús Flores-Soler2, Ahmed Chamaisse-Akari2, Angela Mclnerney2, Carlos Vergara-Uzcategui2, Lin Wang2, Juan J González-Ferrer2, David Filgueiras-Rama2, Victoria Cañadas-Godoy2, Carlos Macaya-Miguel2,3,4,5, Julián Pérez-Villacastín2,3,4,5.
Abstract
INTRODUCTION: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes a severe respiratory disease with a 3% global mortality. In the absence of effective treatment, controlling of risk factors that predispose to severe disease is essential to reduce coronavirus disease 2019 (COVID-19) mortality. Large observational studies suggest that exercise can reduce the risk of all-cause and disease-specific mortality. The aim of this study was to analyze the influence of the baseline physical activity level on COVID-19 mortalityEntities:
Keywords: COVID-19; Exercise; Physical activity; Physical training; SARS-CoV-2
Year: 2021 PMID: 33715099 PMCID: PMC7955903 DOI: 10.1007/s40121-021-00418-6
Source DB: PubMed Journal: Infect Dis Ther ISSN: 2193-6382
Fig. 1Inclusion flow diagram
Comparison of baseline characteristics and in-hospital outcomes between groups
| Group 1 ( | Group 2 ( | ||
|---|---|---|---|
| Age (years) | 56.0 (45.9–64.6) | 52.7 (42.9–60.7) | 0.007 |
| Female gender | 141 (47.5%) | 97 (43.5%) | 0.268 |
| Ethnic group | |||
| Caucasian | 231 (77.8%) | 179 (76.2%) | 0.722 |
| Latino | 56 (18.9%) | 47 (21.1%) | |
| Black | 2 (0.7%) | 0 (0%) | |
| Asian | 3 (1%) | 3 (1.1%) | |
| Other | 5 (1.7%) | 3 (1.3%) | |
| Hypertension | 107 (36%) | 55 (24.7%) | 0.006 |
| Diabetes mellitus | 44 (14.8%) | 25 (11.2%) | 0.231 |
| Dyslipidemia | 94 (31.6%) | 57 (25.6%) | 0.118 |
| Active smoker | 20 (6.7%) | 8 (3.6%) | 0.131 |
| Former smoker | 45 (14.2%) | 25 (11.2%) | 0.230 |
| Obesity (BMI > 30 kg/m2) | 70 (23.6%) | 36 (16.1%) | 0.086 |
| Heart disease | 34 (11.4%) | 18 (8.1%) | 0.205 |
| Coronary disease | 10 (3.4%) | 6 (2.7%) | 0.658 |
| Valvular disease | 2 (0.7%) | 1 (0.4%) | 0.606 |
| Heart failure | 7 (2.4%) | 2 (0.9%) | 0.312 |
| Mixed cardiomyopathy | 7 (2.4%) | 1 (0.4%) | 0.146 |
| Arrhythmias | 8 (2.7%) | 8 (3.6%) | 0.559 |
| Impaired renal function | 28 (9.4%) | 4 (1.8%) | < 0.001 |
| Pulmonary disease | 51 (17.2%) | 25 (11.2%) | 0.057 |
| Asthma | 14 (4.7%) | 13 (5.8%) | 0.570 |
| Chronic obstructive pulmonary disease | 20 (6.7) | 5 (2.2%) | 0.018 |
| Restrictive disease | 2 (0.7%) | 1 (0.4%) | 0.606 |
| Other | 15 (5.1%) | 6 (2.7%) | 0.176 |
| Home oxygen therapy | 5 (1.7%) | 5 (2.1%) | 0.752 |
| Cerebrovascular disease | 18 (6.1%) | 3 (1.3%) | 0.007 |
| Connective tissue disease | 15 (5.1%) | 4 (1.8%) | 0.050 |
| Liver disease | 19 (6.4%) | 4 (1.8%) | 0.012 |
| Malignancy | 36 (12.2%) | 20 (9%) | 0.234 |
| Physical dependency states | 22 (7.4%) | 2 (0.9%) | < 0.001 |
Symptoms, signs, and main analytical findings at admission
| Symptoms and signs | |||
| Admission SatO2 (%) | 93.0 (89.5–98.0) | 96 (93–98) | 0.075 |
| Asymptomatic | 10 (3.4%) | 7 (3.1%) | 0.911 |
| Dyspnea | 166 (55.9%) | 126 (56.5%) | 0.853 |
| Tachypnea (> 20 bpm) | 55 (18.5%) | 21 (9.4%) | 0.004 |
| Asthenia | 105 (35.4%) | 62 (27.8%) | 0.052 |
| Hypo/anosmia | 26 (8.8%) | 22 (9.9%) | 0.621 |
| Dysgeusia | 20 (6.7%) | 23 (10.3%) | 0.125 |
| Sore throat | 18 (6.1%) | 13 (5.8%) | 0.944 |
| Fever (> 38 °C) | 241 (81.1%) | 196 (87.9%) | 0.043 |
| Cough | 230 (77.4%) | 173 (77.6%) | 0.912 |
| Vomiting | 23 (7.7%) | 11 (4.9%) | 0.221 |
| Diarrhea | 78 (26.3%) | 48 (21.5%) | 0.251 |
| Myalgia | 93 (31.3%) | 82 (36.8%) | 0.135 |
| Main analytical findings | |||
| Creatinine (mg/dl) | 0.80 (0.65–1.00) | 0.79 (0.66–0.96) | 0.875 |
| Leukocytes (U/mm3) | 5900 (4600–8300) | 5800 (4500–7900) | 0.674 |
| Lymphocytes (U/mm3) | 900 (600–1400) | 1000 (600–1300) | 0.733 |
| Platelets (103 U/mm3) | 194 (146–255) | 205 (150–257) | 0.523 |
| Raised | 186 (62.6%) | 130 (58.3%) | 0.223 |
| Raised procalcitonin (> 0.05 ng/ml) | 76 (25.6%) | 49 (22%) | 0.286 |
| Raised C-reactive protein (> 0.5 mg/dl) | 279 (93.9%) | 200 (89.7%) | 0.036 |
| Raised troponin I (> 0.05 ng/ml) | 17 (5.7%) | 10 (4.5%) | 0.528 |
| Raised transaminases (> 40 U/l) | 142 (47.8%) | 104 (46.6%) | 0.775 |
| Raised ferritin (> 340 mg/dl) | 176 (59.3%) | 132 (59.2%) | 0.767 |
| Raised lactate dehydrogenase (> 480 U/l) | 225 (75.8%) | 167 (74.9%) | 0.435 |
Infection severity and treatment
| Infection severity | |||
| Hospital stay (days) | 8 (5–13) | 7 (5–10) | 0.024 |
| Maximum temperature (°C) | 37.9 (37–38.5) | 38.0 (37–38.8) | 0.117 |
| Pneumonia | 276 (92.9%) | 203 (91%) | 0.297 |
| Unilateral | 51 (17.2%) | 45 (20.2%) | 0.395 |
| Bilateral | 225 (75.8%) | 158 (70.9%) | 0.172 |
| Sepsis | 49 (16.5%) | 24 (10.8%) | 0.072 |
| Systemic inflammatory response syndrome | 56 (18.9%) | 27 (12.1%) | 0.042 |
| Respiratory failure | 160 (53.9%) | 80 (35.9%) | < 0.001 |
| Heart failure | 11 (3.7%) | 3 (1.3%) | 0.101 |
| Renal failure | 43 (14.5%) | 14 (6.3%) | 0.003 |
| Therapy during the hospitalization | |||
| Corticosteroids | 103 (34.7%) | 55 (24.7%) | 0.011 |
| Hydroxychloroquine | 253 (85.2%) | 194 (87%) | 0.548 |
| Lopinavir–ritonavir | 200 (67.3%) | 176 (78.9%) | 0.002 |
| Interferon-β1 | 23 (7.7%) | 22 (9.9%) | 0.417 |
| Tocilizumab | 39 (13.1%) | 23 (10.3%) | 0.300 |
| Anticoagulation | 124 (41.8%) | 85 (38.1%) | 0.976 |
| Respiratory support | |||
| Oxygen therapy | 206 (69.4%) | 137 (61.4%) | 0.070 |
| High-flow nasal cannula | 72 (24.2%) | 53 (23.8%) | 0.864 |
| Non-invasive mechanical ventilation | 48 (16.2%) | 50 (22.4%) | 0.066 |
| Invasive mechanical ventilation | 23 (7.7%) | 10 (4.5%) | 0.135 |
| Prone position for ventilation | 28 (9.4%) | 21 (9.4%) | 0.949 |
| Critical care unit admission | 26 (8.8%) | 14 (6.3%) | 0.294 |
Categorical variables were described by absolute frequencies and relative frequencies were expressed as a percentage. The quantitative variables that presented non-normal distribution were expressed in median and interquartile range
BMI body mass index, bmp breaths per minute, SatO2 oxygen saturation
Fig. 2Kaplan–Meier survival analysis
Mortality
| HR | 95% CI | |||
|---|---|---|---|---|
| Lower | Higher | |||
| Sedentary lifestyle | 8.13 | 2.91 | 22.70 | < 0.001 |
| Age (per 1-year increased) | 1.09 | 1.06 | 1.13 | < 0.001 |
| Male | 1.83 | 0.99 | 3.37 | 0.054 |
| Non-Caucasian race | 0.70 | 0.33 | 1.50 | 0.357 |
| Hypertension | 3.54 | 1.98 | 6.34 | < 0.001 |
| Diabetes mellitus | 1.54 | 0.74 | 3.18 | 0.246 |
| Obesity | 1.58 | 0.83 | 3.01 | 0.164 |
| Smoking habit (former and active) | 3.57 | 1.99 | 6.41 | < 0.001 |
| Renal disease | 4.75 | 2.36 | 9.55 | < 0.001 |
| Pulmonary disease | 3.35 | 1.83 | 6.12 | < 0.001 |
| Heart disease (coronary disease and heart failure) | 2.69 | 1.06 | 6.80 | 0.037 |
| Cerebrovascular disease | 5.58 | 2.61 | 11.94 | < 0.001 |
| Connective tissue disease | 3.28 | 1.30 | 8.31 | 0.012 |
| Liver disease | 2.79 | 1.10 | 7.06 | 0.030 |
| Malignancy | 4.09 | 2.17 | 7.71 | < 0.001 |
| Physical dependency | 6.50 | 3.23 | 13.08 | < 0.001 |
Univariate Cox regression
CI confidence interval, HR hazard ratio
Fig. 3Multivariable Cox regression
| The SARS-CoV-2 infection causes a severe respiratory disease with a 3% global mortality. |
| Patients with cardiovascular risk factors (hypertension, diabetes, obesity, and smokers) and previous systemic diseases (heart, pulmonary, renal, liver, cerebrovascular disease, or oncological pathologies) have been shown to have a poorer prognosis with coronavirus infection. |
| Large observational studies also suggest that exercise itself can reduce the risk of all-cause and disease-specific mortality and it is associated with decreased levels of inflammation markers. |
| It is reasonable that regular physical activity may influence the evolution of the SARS-CoV-2 infection, favoring a better prognosis. |
| In this study, a baseline sedentary lifestyle increases the mortality of hospitalized patients with COVID-19 independently of other previously described risk factors (hazard ratio 5.91 (1.80–19.41); |
| This finding may be of great utility in the prevention of severe COVID-19 disease. |